Drug intelligence / Profile preview

AMAVIT D3

Development stage
Unknown
Lead developer
Amara Therapeutics
Modality
Small Molecules
Administration
Oral
01

Overview

AMAVIT D3 is a line of dietary supplements developed and manufactured by the Polish pharmaceutical company Amara. The product line contains vitamin D3 (cholecalciferol) and is designed to support the maintenance of healthy bones and teeth, proper muscle function, and the normal operation of the immune system. AMAVIT D3 is available in various formulations and strengths tailored to different age groups, including AMAVIT D3 Baby (400 IU drops in MCT oil), AMAVIT D3 Junior (1000 IU orally disintegrating tablets), AMAVIT D3 (2000 IU orally disintegrating tablets or soft capsules), and AMAVIT D3 MAX (4000 IU orally disintegrating tablets). The orally disintegrating tablet (ODT) formulations feature a pleasant lemon flavor and are designed to dissolve quickly in the mouth without the need for water, making them suitable for individuals who have difficulty swallowing capsules or tablets.

Brand names
AMAVIT D3AMAVIT D3 BabyAMAVIT D3 JuniorAMAVIT D3 MAX
02

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on AMAVIT D3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMAVIT D3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call